16 results about "Pazopanib" patented technology

The invention discloses an application of a therapeutic target spot in preparation of a drug for treating targeted therapy resistance of kidney cancer. The therapeutic target spot is SLC27A3. The SLC27A3 comprises an SLC27A3 gene and a coding sequence thereof, an expression product of the SLC27A3 gene and a coding sequence thereof, and the SLC27A3 gene and an active fragment or derivative of the expression product thereof; the nucleotide of the SLC27A3 is as shown in SEQ ID NO. 1. According to the invention, a therapeutic target SLC27A3 is knocked out or silenced, and a compound Parishin for resisting the SLC27A3 protein is provided, so that the resistance of renal clear cell carcinoma cells to the pezopanib is remarkably improved, and the sensitivity of renal carcinoma cells to the pezopanib is enhanced.

Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.

A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

The invention discloses a preparation method of pazopanib hydrochloride, and belongs to the technical field of pharmaceutical chemistry synthesis. Comprising the following steps: (1) reacting a compound II with a compound III under the action of alkali to obtain a compound IV; (2) carrying out fixed bed oxidation amination reaction on the compound V to obtain a compound VI; and (3) reacting the compound IV with a compound VI to obtain pazopanib hydrochloride (compound I). The method has the advantages of easily available raw materials, mild reaction conditions and low production cost, can reduce the risk of production operation, and is suitable for industrial production. # imgabs0 #

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.

The invention relates to a preparation method of pazopanib and an intermediate thereof, in particular to a preparation method of a structure as shown in a formula IV and a method for further preparing the pazopanib. 4-chloro-2-nitropyrimidine is used as an initial raw material and is sequentially subjected to substitution, reduction and alkylation reaction to obtain the pazopanib. The preparation method provided by the invention is a brand new technical route and is not reported in any literature and patent. According to the method, the yield of the product can be greatly improved, and the method is suitable for industrial production.

Provided are pharmaceutical compositions which include an amorphous solid dispersion comprising i) a lipophilic active pharmaceutical ingredient such as abiraterone, alectinib, pazopanib, cabozantinib, venetoclax, lurasidone, or vilazodone or a salt thereof, ii) a hydrophilic polymer, iii) optionally a surfactant, iv) optionally an adsorbent, and v) optionally an acid. Also described are methods for preparing such pharmaceutical compositions and treating a subject in need thereof. In one aspect, disclosed herein is an amorphous solid dispersion comprising an active pharmaceutical ingredient.

The invention provides a renal clear cell carcinoma pazopanib drug-resistant cell strain as well as a construction method and application thereof, the preservation number of the renal clear cell carcinoma drug-resistant cell strain is GDMCC NO: 65811, and the renal clear cell carcinoma drug-resistant cell strain is a pazopanib drug-resistant cell strain of 786-O. The Pazopanib is constructed in a manner of inducing the proliferation of kidney cancer cells 786-O in the Pazopanib by adopting a method of gradually increasing the concentration, and the drug resistance molecular mechanism of the Pazopanib is analyzed and read comprehensively through transcriptome, so that a new treatment idea is provided for clinically coping with the drug resistance of the Pazopanib.

Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.

The present invention provides a pazopanib-resistant renal clear cell carcinoma cell line, a construction method, and an application thereof. The deposit number of the renal clear cell carcinoma cell line is GDMCC NO: 65811. The renal clear cell carcinoma cell line is a 786-O pazopanib-resistant cell line. The cell line is constructed by inducing the proliferation of renal cancer cells 786-O in the presence of pazopanib by gradually increasing the concentration of pazopanib. Through comprehensive transcriptome analysis, the molecular mechanism of drug resistance is interpreted, providing a new treatment strategy for clinical treatment of drug resistance.

This application relates, in certain embodiments, to a method and composition for treating soft tissue sarcomas (STS, e.g., spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma) using a composition comprising nanoparticles containing an mTOR inhibitor (e.g., limus drugs, e.g., sirolimus or its derivatives) and albumin in combination with a multityrosine kinase inhibitor (e.g., pazopanib).

A breakpoint cluster region-Abelson (Bcr-Abl) inhibitor for use in a method of treating a skin condition or disease, such as keloid disease (KD) or folliculitis keloidalis nuchae (FKN), is provided The Bcr-Abl inhibitor can be GNF-2, GNF-5 or ON012380. Optionally, the Bcr-Abl inhibitor can be administered in combination with one or more 4-anilinoquinazolines, such as dasatinib, nilotinib, bosutinib, axitinib, ponatinib, rociletinib, vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, lapatinib, sunitinib, sorafenib or pazopanib. A UDP- glucuronosyltransferase (UGT) inhibitor, such as magnolol, can also be administered in an optional second treatment step, typically about 2 to 4 weeks after the first treatment. One or more 4-anilinoquinazolines can also be administered in the second treatment step. A Bcr-Abl inhibitor and / or one or more 4-anilinoquinazolines can further be administered in an optional third treatment step, typically about 6 weeks after the first treatment. A method of treatment and a kit are also provided.

A method for treating adenoid cystic carcinoma (ACC) is provided, comprising co-administering at least inhibitor of cyclin-dependent kinase 4 / 6 (CDK 4 / 6) and at least one multi-targeted receptor tyrosine kinase inhibitor (mtRTKI). The CDK 4 / 6 inhibitor may be at least one of palbociclib, abemaciclib and ribociclib and the mtRTKI may be at least one of sunitinib, sorafenib and pazopanib. A combination therapy with palbociclib and sunitinib provides a synergic effect in treatment of ACC.

To provide methods for applying to the skin an anti-vascular endothelial growth factor (VEGF) to treat various skin conditions.SOLUTION: A therapeutically effective amount of at least one anti-VEGF-containing compound is topically applied to a target region of the skin by using a microneedle. The anti-VEGF-containing compound is selected from anti-VEGF antibodies such as bevacizumab and ranibizumab, or tyrosine kinase inhibitors such as pegaptanib, imatinib, vandetanib, sorafenib, pazopanib, erlotinib and gefitinib. Further, the compound may comprise at least one filler selected from NSAID, hyaluronic acid, collagens, elastin, proteoglycan, chondroitin sulfate, heparin sulfate, elastin, fibrillin and fibrin or a combination thereof.SELECTED DRAWING: None

Disclosed herein are nanoparticles comprising Pazopanib or a derivative thereof encapsulated by the copolymer poly (lactic-co-glycolic acid) (PLGA). Also disclosed herein are methods for treating osteoarthritis, inhibiting or preventing cartilage degeneration, and reducing or inhibiting pain-associated depression in subjects with joint pain with nanoparticles comprising Pazopanib or a derivative thereof.

Provided is a pharmaceutical composition comprising an amorphous solid dispersion comprising: i) a lipophilic active pharmaceutical ingredient, such as abiraterone, alectinib, pazopanib, cabozantinib, vetoclax, lurasidone, or vilazodone, or a salt thereof, and i) a lipophilic active pharmaceutical ingredient, such as abiraterone, alectinib, pazopanib, cabozantinib, vetoclax, lurasidone, or vilazodone, or a salt thereof; ii) a hydrophilic polymer; iii) optionally a surfactant; iv) optionally an adsorbent; and v) optionally an acid. Also described are methods for preparing such pharmaceutical compositions and treating a subject in need thereof. In one aspect, disclosed herein is an amorphous solid dispersion comprising an active pharmaceutical ingredient.